Clinical Trials Logo

Methylmalonic Acidemia (MMA) clinical trials

View clinical trials related to Methylmalonic Acidemia (MMA).

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03810690 Withdrawn - Clinical trials for Metabolism, Inborn Errors

Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia

Start date: May 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency between 1 to 18 years of age with elevated plasma methylmalonic acid. The study is designed to characterize baseline biomarker levels followed by assessment of safety, pharmacokinetics, and pharmacodynamics of different doses of mRNA-3704 in patients affected by MMA as part of the Dose Escalation phase. During the Dose Escalation phase, three dose levels of mRNA-3704 are planned to be investigated in this study among patients with MMA due to MUT deficiency: low dose, mid dose, and high dose. An additional cohort to evaluate a fourth dose level may be considered jointly by the independent SMC and the Sponsor. Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional patients will be enrolled in a Dose Expansion phase to allow for further characterization of the safety and pharmacodynamics of mRNA-3704. Patients in both phases of study will participate in a pre-dosing observational period, followed by a treatment period, and then a follow-up period after withdrawal of treatment.